Company intelligence / Profile preview

Genemo

San Diego and/or New York, California, United States

Ownership: Private
Development stage: Other

Overview

Genemo has developed an extracellular RNA sequencing service, with notable collaborative research identifying PHGDH RNA as a blood biomarker for early detection of Alzheimer's disease. Their technology is used in clinical studies and aims for companion diagnostic development.

Therapeutic areas: Neurology
Modalities: RNA-based diagnosticsRNA sequencingCompanion diagnostic
Industry: Molecular Diagnostics

Partnerships

UC San Diego

Beyond the preview

Go deeper on Genemo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genemo.

Explore the full profile